Physitrack CEO Henrik Molin discusses the company's Q2 report, highlighting roughly 10% year-to-date growth and a seventh consecutive quarter of positive operating cash flow. He details the US launch of RTM (Remote Therapeutic Monitoring) — now live with one of the country's largest hospital systems and over 100 active sales discussions — the cross-sell potential between LifeCare and Champion Health under the new "Project Physia" initiative, and the company's new long-term incentive program aimed at attracting and retaining talent in the US market.

Läs mer på Redeye

Ämnen i artikeln


Physitrack

Senast

8,30

1 dag %

−3,26%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån